Compare ACADIA Pharmaceuticals Inc. (ACAD) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs SoundHound AI Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.81 (market cap $5.07B), while SoundHound AI Inc trades at $7.39 (market cap $3.29B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | SOUN | |
|---|---|---|
Market Cap | $5.07B | $3.29B |
Sector | Health | Technology |
52-Week High | $29.41 | $21.40 |
52-Week Low | $20.06 | $5.70 |
Enterprise Value | $4.19B | $3.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
SoundHound AI (SOUN) trades at $7.395, down 0.87% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, revenue grew 45% year-over-year to $61.9 million, and the company raised its 2026 revenue guidance, driven by its OASYS platform. However, the stock faces headwinds from negative net income margins and high cash burn.
The outlook is cautiously optimistic with 75% of analysts rating it Buy and a $8.50 consensus target, but profitability challenges and premium valuations pose risks. Key catalysts include the pending LivePerson acquisition and OASYS adoption, while execution on path to profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
